2026-01-13 - Analysis Report
**Company Overview**
Merck & Co Inc, a pharmaceutical company.


**Return Rate Comparison**

* Cumulative return of review stock (MRK): **26.09%**
* Cumulative return of comparison stock (S&P 500, VOO): **94.34%**
* Degree of divergence (simply the difference in cumulative return on the last day of the data): **-68.25%**

**Alpha, Beta Analysis**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2016-2018  | 24.00% | 14.7% | 21.00% | 0.70 | 182.10B |
| 2017-2019  | 37.00% | 14.7% | 20.00% | 0.70 | 216.80B |
| 2018-2020  | 13.00% | 19.3% | -8.00% | 0.70 | 195.00B |
| 2019-2021  | 0.00% | 19.3% | -43.00% | 0.60 | 191.40B |
| 2020-2022  | 14.00% | 16.3% | 16.00% | 0.50 | 277.10B |
| 2021-2023  | 31.00% | 14.3% | 30.00% | 0.30 | 272.30B |
| 2022-2024  | -5.00% | 24.9% | -24.00% | 0.30 | 248.50B |
| 2023-2025  | -24.00% | 39.0% | -86.00% | 0.30 | 262.90B |


**Recent Stock Price Fluctuations**

* Close: **$109.19**
* Last-market: {'price': 109.19, 'previousClose': 110.53, 'change': -1.21}
* 5-day SMA: **$109.64**
* 20-day SMA: **$105.14**
* 60-day SMA: **$96.84**

**RSI, PPO Analysis**

* Market Risk Indicator (MRI): 0.80
* RSI: 76.51
* PPO: 0.11
* Recent (20 days) relative divergence change: 1.40 (+): improving
* 7-day Rank change: -3 (-): rank down
* 7-day Dynamic Expected Return change: 0.60 (+): improving
* Expected Return (%): **-26.70%**
* If {'price': 109.19, 'previousClose': 110.53, 'change': -1.21} is large, reflect the fluctuation issue (sharp rebound, sharp decline).

**Recent News & Significant Events**

* [2026-01-12] Merck (MRK) stock slides as JPMorgan conference tests deal buzz and vaccine risk - TechStock² (news.google.com)
* [2026-01-12] Merck stock rating reiterated at Buy by UBS on cancer drug potential - Investing.com (news.google.com)
* [2025-12-24] Is Merck Stock’s Run Legitimate? - Forbes (news.google.com)
* [2025-12-16] Merck (MRK) Price Target Lifted at Morgan Stanley as Biopharma Outlook Improves - Yahoo Finance (news.google.com)
* [2026-01-09] What Is Happening With Merck Stock? - Trefis (news.google.com)
* [2026-01-12] Merck & Co., Inc. $MRK Shares Sold by Tokio Marine Asset Management Co. Ltd. - MarketBeat (news.google.com)

**Analyst Opinions**

Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 1.90 (~Buy)
- Opinions: 27
- Target Price (avg/high/low): 113.33 / 135.00 / 83.00

**Recent Earnings Analysis**

| Date | EPS | Revenue |
|---|---:|---:|
| 2025-11-05 | 2.32 | 17.28 B$ |
| 2025-08-05 | 1.76 | 15.81 B$ |
| 2025-05-02 | 2.01 | 15.53 B$ |
| 2024-11-06 | 1.25 | 16.66 B$ |
| 2025-11-05 | 1.25 | 16.66 B$ |

**Financial Information**

### Revenue and Profitability

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $17.28B | 77.69% |
| 2025-06-30 | $15.81B | 77.50% |
| 2025-03-31 | $15.53B | 77.98% |
| 2024-12-31 | $15.62B | 75.50% |
| 2024-09-30 | $16.66B | 75.51% |

### Capital and Profitability

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $51.85B | 11.16% |
| 2025-06-30 | $48.99B | 9.04% |
| 2025-03-31 | $48.34B | 10.51% |
| 2024-12-31 | $46.31B | 8.08% |
| 2024-09-30 | $44.50B | 7.09% |

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.